ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

APLM Apollomics Inc

0.22
0.0144 (7.00%)
After Hours
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 767,882
Bid Price 0.202
Ask Price 0.22
News -
Day High 0.21

Low
0.1854

52 Week Range

High
6.20

Day Low 0.1854
Company Name Stock Ticker Symbol Market Type
Apollomics Inc APLM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0144 7.00% 0.22 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.2049 0.1854 0.21 0.201 0.2056
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,663 767,882 $ 0.1992259 $ 152,982 - 0.1854 - 6.20
Last Trade Time Type Quantity Stock Price Currency
19:33:41 20 $ 0.22 USD

Apollomics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
18.23M 86.80M - 1.22M -172.6M -1.99 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Apollomics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No APLM Message Board. Create One! See More Posts on APLM Message Board See More Message Board Posts

Historical APLM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.230.23850.18540.2210948477,588-0.01-4.35%
1 Month0.3510.36750.18540.2753859709,883-0.131-37.32%
3 Months0.5910.750.18540.3628577368,768-0.371-62.77%
6 Months0.78751.050.18540.547591299,627-0.5675-72.06%
1 Year4.826.200.18540.86571351,038,711-4.60-95.44%
3 Years18.6049.000.18541.25903,314-18.38-98.82%
5 Years18.6049.000.18541.25903,314-18.38-98.82%

Apollomics Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Your Recent History

Delayed Upgrade Clock